GlobeNewswire
-
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
06/04/2026 -
Sienna Senior Living recognized by The Globe and Mail’s Women Lead Here Benchmark
06/04/2026 -
Adaptin Bio Shares to be Quoted on the OTCQB Under Ticker Symbol APTN
06/04/2026 -
Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure
06/04/2026 -
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care
06/04/2026 -
Egg Medical Launches EggNest™ Complete Flex: Apron-Free Protection Without Construction, Downtime or Disruption
06/04/2026 -
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
06/04/2026 -
Flare Therapeutics Announces Three Upcoming Poster Presentations at AACR Annual Meeting 2026
06/04/2026 -
Egg Medical présente EggNest™ Complete Flex : une protection sans tablier, sans travaux, sans interruption de service ni perturbation
06/04/2026 -
OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Data
06/04/2026 -
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
06/04/2026 -
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/04/2026 -
Stablecoin Development Corporation Begins Trading on NYSE American Under Ticker “SDEV”
06/04/2026 -
TOMI Environmental Solutions, Inc. Announces Surge in SteraMist Adoption Across Compounding Pharmacy Industry Amid Tightening Regulatory Standards
06/04/2026 -
Stereotaxis Announces FDA Clearance and Launch of Synchrony System
06/04/2026 -
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
06/04/2026 -
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
06/04/2026 -
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor
06/04/2026 -
ANNA Autism Care Appoints Ariana Boutain, PhD, BCBA-D as Chief Clinical Officer
06/04/2026
Pages